Vertex Pharmaceuticals missed Wall Street estimates for third-quarter sales on Monday, hurt by weaker-than-expected demand for its older cystic fibrosis treatments.
Four years after a single dose of SRP-9001 gene therapy, four children with Duchenne muscular dystrophy show sustained stabilization of motor function that would otherwise show expected decline.